The Federal Trade Commission (FTC) has begun outlining its case against Edwards Lifesciences’ proposed purchase of heart implant developer JenaValve after the antitrust agency announced it would move to block the $945 million acquisition this past summer. In an opening statement presentation (PDF) posted to the FTC’s website, the commission said that if the deal is allowed to continue, Edwards would be left in control of the only two potential transcatheter aortic valve replacement (TAVR) systems designed to stem the backflow of blood through the heart’s chambers. That would effectively allow the company to pick a winner and discard the other, according to the FTC, and create a monopoly in the indication.
Read the full article: FTC Outlines Antitrust Case Against Edwards’ $945M JenaValve Acquisition //
Source: https://www.fiercebiotech.com/medtech/ftc-outlines-antitrust-case-against-edwards-945m-jenavalve-acquisition-not-transaction-we